Xerostomia (Dry Mouth) Therapeutics Industry Size, Manufacturing cost, Top Key Players Forecast 2025
Xerostomia (Dry Mouth) Therapeutics Market is anticipated to reach USD 796.1 million and is anticipated to grow at a CAGR of 3.2% in the years to come. Xerostomia is a clinical condition of dry mouth and does not show the signs of hyposalivation and symptoms on frequent terms
Xerostomia (Dry Mouth) Therapeutics Market is anticipated to reach USD 796.1 million and is anticipated to grow at a CAGR of 3.2% in the years to come. Xerostomia is a clinical condition of dry mouth and does not show the signs of hyposalivation and symptoms on frequent terms
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Xerostomia</strong> (<strong>Dry</strong> <strong>Mouth</strong>) <strong>Therapeutics</strong> <strong>Industry</strong> <strong>Size</strong>,<br />
<strong>Manufacturing</strong> <strong>cost</strong>, <strong>Top</strong> <strong>Key</strong> <strong>Players</strong> <strong>Forecast</strong> <strong>2025</strong><br />
“<strong>Xerostomia</strong> (<strong>Dry</strong> <strong>Mouth</strong>) <strong>Therapeutics</strong> Market is anticipated to reach USD<br />
796.1 million and is anticipated to grow at a CAGR of 3.2% in the years to<br />
come. <strong>Xerostomia</strong> is a clinical condition of dry mouth and does not show the<br />
signs of hyposalivation and symptoms on frequent terms.”<br />
The global <strong>Xerostomia</strong> (<strong>Dry</strong> <strong>Mouth</strong>) <strong>Therapeutics</strong> Market is anticipated to reach USD 796.1 million and is<br />
anticipated to grow at a CAGR of 3.2% in the years to come. <strong>Xerostomia</strong> is a clinical condition of dry mouth and<br />
does not show the signs of hyposalivation and symptoms on frequent terms. This condition is observed when<br />
the rate of saliva flow is low in comparison with absorption across the oral mucosa coupled with rate of fluid<br />
evaporation from the mouth. Prolonged xerostomia is a significant disease in patients since it affects speech,<br />
chewing, denture-wearing, and swallowing activities. The defined causes of hyposalivation and xerostomia are<br />
the use of several medications such as antidepressants, anticoagulants, antiretroviral, hypoglycemics,<br />
multivitamins and supplements, and anti-inflammatory drugs. Prevalence of xerostomia persists in a large<br />
population with different age groups despite following medical or dental consultation.<br />
Rise in use of prescribed medication coupled with rising prevalence of HIV and cancer are expected to act as<br />
primary drivers for market growth. Secondary factors such as easy availability of <strong>cost</strong>-effective medications<br />
along with rise in preference for prescription drugs act as market drivers. In addition, rising cases of depression,<br />
Parkinson’s disease, HIV, and hypertension are also expected to contribute significantly to the market<br />
development. The market is further triggered by rise in cases of chronic xerostomia due to intake of certain<br />
medications. However, significant <strong>cost</strong>s and uneven medical infrastructure arelikely to hinder the market<br />
growth in the forecast period upto <strong>2025</strong>. <strong>Xerostomia</strong> (<strong>Dry</strong> mouth) therapeutics market is segmented into type,<br />
product, and region. Type category includes prescription and OTC.<br />
Request Sample Copy of this Market Research @<br />
https://www.millioninsights.com/industry-reports/xerostomia-dry-mouth-therapeutics-market/request-sample
“Over-the-counter (OTC)” segment accounts for a larger share and is expected to gain significant momentum<br />
in the forecast period owing to wide variety & availability of branded drugs and low-<strong>cost</strong> products. Product<br />
segmentation includes salivary substitutes, salivary stimulants, and dentrifices. Dentrifices segment accounted<br />
for a significant market share owing to effectiveness, affordability and higher adoption.Geographic<br />
segmentation for xerostomia (dry mouth) therapeutics industry includes North America, South America, Europe,<br />
Asia-Pacific, Middle East and Africa.<br />
Asia-Pacific’s xerostomia therapeutics market is anticipated to rise at a CAGR of 4.2% in the forthcoming period<br />
due to rising awareness, high prevalence of Parkinson’s disease, cancer and HIV. North America followed by<br />
Europe accounts for a higher revenue share owing to rising prevalence of xerostomia and other dry mouth<br />
diseases such as rheumatoid arthritis, Sjogren’s syndrome and HIV along with rising awareness by government<br />
and health care NGOs.<br />
Browse Full Research Report @<br />
https://www.millioninsights.com/industry-reports/xerostomia-dry-mouth-therapeutics-market<br />
The key players in the xerostomia (dry mouth) therapeutics market include GlaxoSmithKline plc; Church &<br />
Dwight Co., Inc.; Colgate-Palmolive Company; Hikma Pharmaceuticals PLC; Pendopharm; Sun Pharmaceuticals<br />
Industries Ltd.; Lupin Pharmaceuticals, Inc.; Pfizer, Inc.; Parnell Pharmaceuticals, Inc.; Acacia Pharma; and<br />
OraCoat.<br />
Market Segment:<br />
Type Outlook (Market Revenue in USD Million, 2014 - <strong>2025</strong>)<br />
• OTC<br />
• Prescription<br />
Product Outlook (Market Revenue in USD Million, 2014 - <strong>2025</strong>)<br />
• Salivary Stimulants<br />
• Salivary Substitutes<br />
• Dentifrices<br />
Regional Outlook (Revenue, USD Million, 2014 - <strong>2025</strong>)<br />
• North America<br />
• U.S.<br />
• Canada<br />
• Europe<br />
• Germany<br />
• UK
• Asia Pacific<br />
• China<br />
• Japan<br />
• India<br />
• Latin America<br />
• Brazil<br />
• Mexico<br />
• Middle East & Africa<br />
• South Africa<br />
See More Reports of this Category by Million Insights @<br />
https://www.millioninsights.com/industry/healthcare<br />
Get in touch<br />
At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our<br />
representatives strive to understand diverse client requirements and cater to the same with the<br />
most innovative and functional solutions.<br />
Contact Person:<br />
Ryan Manuel<br />
Research Support Specialist, USA<br />
Email: ryan@millioninsights.com<br />
Global Headquarters<br />
Million Insights<br />
Felton Office Plaza 6265 Highway 9 Felton, California 95018, United States<br />
Phone: 1-408-610-2300<br />
Email: sales@millioninsights.com<br />
Asia Pacific<br />
Million Insights<br />
Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar, Pune, MH, 411016<br />
India<br />
Phone: 91-20-65300184
Change language